A retrospective review of the therapeutic response with remission in patients with newly diagnosed bullous pemphigoid.
We reviewed the clinical characteristics and therapeutic response in cases of newly diagnosed bullous pemphigoid at the National Skin Centre between June 2009 and December 2010. Most (76%, n = 68/90) achieved clinical remission within 6 months of commencement of therapy. Oral mucosal involvement was identified as a risk factor associated with a prolonged duration of treatment beyond 6 months.
Department of Dermatology, National Skin Centre, Singapore.
Sai Yee
SY
Chuah
Suat Hoon
SH
Tan
Sze Hon
SH
Chua
Mark B Y
MB
Tang
Yen Loo
YL
Lim
Ching Yin
CY
Neoh
Audrey W H
AW
Tan
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa; D010391:Pemphigoid, Bullous / Q000175:diagnosis / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*; D012074:Remission Induction; D012189:Retrospective Studies; D014803:Vitamin B Complex / Q000627:therapeutic use; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014803:Vitamin B Complex; D011239:Prednisolone
autoimmune disease; bullous pemphigoid; remission; therapeutic response